| 000 | 02290 am a22003013u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aBailey, Robert C. _eauthor _92375 |
| 700 | 1 | 0 |
_aKimani, Makobu _eauthor _92376 |
| 700 | 1 | 0 |
_aKabuti, Rhoda _eauthor _92377 |
| 700 | 1 | 0 |
_aGumbe, Edwin _eauthor _92378 |
| 700 | 1 | 0 |
_aOtieno, George _eauthor _92379 |
| 700 | 1 | 0 |
_aKimani, Joshua _eauthor _92380 |
| 700 | 1 | 0 |
_aOkall, Duncan _eauthor _92381 |
| 700 | 1 | 0 |
_aSanders, Eduard J. _eauthor _92382 |
| 700 | 1 | 0 |
_aOtieno, Fredrick O. _eauthor _92383 |
| 245 | 0 | 0 | _aURCHOICE: Preferences for Pre-Exposure Prophylaxis (PrEP) Options for HIV Prevention Among Kenyan men who have sex with men and Transgender Women in Nairobi, Kisumu and the Coast |
| 260 | _c2022-06-10. | ||
| 500 | _a/pmc/articles/PMC7614083/ | ||
| 500 | _a/pubmed/35687189 | ||
| 520 | _aHIV prevention method preferences were evaluated among Kenyan men who have sex with men (MSM) and transgender women (TW) from three sites: Kisumu, Nairobi and the Coast. Information sessions detailing the attributes, duration of protection, route of administration and probable visibility were attended by 464 HIV negative participants, of whom 423 (median age: 24 years) agreed to be interviewed. Across pairwise comparisons daily PrEP was by far the least preferred (1%); quarterly injections (26%) and monthly pills (23%) were most preferred, followed by yearly implant (19%) and condoms (12%). When participants were "forced" to choose their most preferred PrEP option, only 10 (2.4%) chose the daily pill; more (37.1%) chose the quarterly injection than the monthly pill (34.8%) and the yearly implant (25.8%). TW preferred the yearly implant over the quarterly injection. To achieve the rates of PrEP uptake and adherence necessary for protecting large proportions of vulnerable MSM and TW, a variety of long-acting products should be developed and made accessible to appeal to a diversity of preferences. | ||
| 540 | _a | ||
| 540 | _ahttps://creativecommons.org/licenses/by/4.0/This work is licensed under a CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) International license. | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nAIDS Behav | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1007/s10461-022-03741-2 _zConnect to this object online. |
| 999 |
_c2260 _d2260 |
||